




RealRate

PHARMACEUTICAL 2017

RespireRx Pharmaceuticals Inc.
Rank 296 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

RespireRx Pharmaceuticals Inc. Rank 296 of 313

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 2,155% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 862% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,460%, being 1,043% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	196
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,727
Liabilities, Non-Current	0
Other Assets	33
Other Compr. Net Income	0
Other Expenses	774
Other Liabilities	0
Other Net Income	16
Property and Equipment	5.2
Research and Development	3,176
Revenues	0
Selling, General and Administrative Expense	5,296

Output Variable	Value in 1000 USD
Assets	234
Liabilities	5,727
Expenses	9,245
Stockholders Equity	-5,493
Net Income	-9,230
Comprehensive Net Income	-9,230
Economic Capital Ratio	-1,460%

